Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524652 | 1.00 | LPL (0.36) | LPLLIPGHIF1AESR1ESR2 | |
| SCHEMBL26991546 | 0.93 | HIF1A (0.39) | LPLLIPGHIF1AJAK2BTK | |
| Heptane SCHEMBL28183875 | 0.91 | LPL (0.41) | LPLLIPG | |
| SCHEMBL31222912 | 0.90 | QDPR (0.41) | HRH3 | |
| SCHEMBL24802990 | 0.89 | QDPR (0.44) | HRH3 | |
| SCHEMBL31223008 | 0.89 | QDPR (0.44) | HRH3 | |
| SCHEMBL24658423 | 0.85 | JAK2 (0.33) | LPLLIPGJAK2BTKROCK1 | |
| SCHEMBL15031645 | 0.83 | HIF1A (0.33) | LPLLIPGHIF1AESR2P2RX7 | |
| SCHEMBL29891190 | 0.82 | HIF1A (0.35) | LPLLIPGHIF1AJAK2BTK | |
| SCHEMBL24746032 | 0.82 | HIF1A (0.35) | LPLLIPGHIF1AJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504733-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP1A1, CYP4B1 | LPL 4701/4885LIPG 4775/4885HIF1A 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.